




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61B 18/12, 18/14	A2	(11) International Publication Number: WO 00/49954 (43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/US00/04973 (22) International Filing Date: 24 February 2000 (24.02.00) (30) Priority Data: 09/256,958 24 February 1999 (24.02.99) US (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US]; One SciMed Place, Maple Grove, MN 55311 (US). (72) Inventors: WENTZEL, David, E.; 18305 Southeast Newport Way, Issaquah, WA 98027 (US). KAVECKIS, Ryan; 2811-84th Avenue West, #101, Seattle, WA 98115 (US). (74) Agents: SEAGER, Glenn, M. et al.; Crompton, Seager & Tufte, LLC, 331 Second Avenue South, Suite 895, Minneapolis, MN 55401 (US).	(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: DEVICE AND METHOD FOR PERCUTANEOUS MYOCARDIAL REVASCULARIZATION



(57) Abstract

Methods and devices for performing percutaneous myocardial revascularization without disrupting the blood pumping activity of the heart. A percutaneous myocardial revascularization system including an active electrode disposed at the end of a catheter and a radio frequency generator coupled to the active electrode for delivering radio frequency energy thereto. Radio frequency energy is selectively applied to the active electrode when the active electrode is properly positioned and when the heart is not in a vulnerable stage of the cardiac rhythm.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DEVICE AND METHOD FOR PERCUTANEOUS MYOCARDIAL REVASCULARIZATION

Related Application

5 The present application is related to U.S. Patent Application Serial No. _____, filed by the same assignee on even date herewith and entitled "PMR Catheter"

Field of the Invention

10 The present invention relates generally to devices and methods for promoting blood circulation to the heart muscle. More particularly, the present invention relates to devices and methods for forming holes, craters or channels in the interior walls of a heart chamber as part of a percutaneous myocardial revascularization (PMR) procedure.

15

Background of the Invention

Assuring that the heart muscle is adequately supplied with oxygen is critical to sustaining the life of a patient. To receive an adequate supply of oxygen, the heart muscle must be well perfused with blood. In a healthy heart,
20 blood perfusion is accomplished with a system of blood vessels and capillaries. However, it is common for the blood vessels to become occluded (blocked) or stenotic (narrowed). A stenosis may be formed by an atheroma which is typically a hard, calcified substance which forms on the walls of a blood vessel.

Historically, individual stenotic lesions have been treated with a number of medical procedures including coronary bypass surgery, angioplasty, and atherectomy. Coronary bypass surgery typically involves utilizing vascular tissue from another part of the patient's body to construct a shunt around the obstructed vessel. Angioplasty techniques such as percutaneous transluminal angioplasty (PTA) and percutaneous transluminal coronary angioplasty (PTCA) are relatively non-invasive methods of treating a stenotic lesion. These angioplasty techniques typically involve the use of a guidewire and a balloon catheter. In these procedures, a balloon catheter is advanced over a guidewire such that the balloon is positioned proximate a restriction in a diseased vessel. The balloon is then inflated and the restriction in the vessel is opened. A third technique which may be used to treat a stenotic lesion is atherectomy. During an atherectomy procedure, the stenotic lesion is mechanically cut or abraded away from the blood vessel wall.

Coronary by-pass, angioplasty, and atherectomy procedures have all been found effective in treating individual stenotic lesions in relatively large blood vessels. However, the heart muscle is perfused with blood through a network of small vessels and capillaries. In some cases, a large number of stenotic lesions may occur in a large number of locations throughout this network of small blood vessels and capillaries. The torturous path and small diameter of these blood vessels limit access to the stenotic lesions. The sheer number and small size of these stenotic lesions make techniques such as cardiovascular by-pass surgery, angioplasty, and atherectomy impractical

When techniques which treat individual lesion are not practical a technique known as percutaneous myocardial revascularization (PMR) may be used to improve the oxygenation of the myocardial tissue. A PMR procedure generally involves the creation of holes, craters or channels directly into the myocardium of the heart. PMR was inspired in part by observations that reptilian heart muscles are supplied with oxygen primarily by blood perfusing directly from within heart chambers to the heart muscle. This contrasts with the human heart, which is supplied by coronary vessels receiving blood from the aorta. Positive clinical results have been demonstrated in human patients receiving PMR treatments. These results are believed to be caused in part by blood flowing within a heart chamber through channels in myocardial tissue formed by PMR. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation. Specifically, the formation of new blood vessels is believed to occur in response to the newly created wound. This response is sometimes referred to as angiogenesis.

In addition to promoting increased blood flow, PMR may also improve the condition of a patient through denervation. Denervation is the elimination of nerve endings. Wounds created during PMR result in the elimination of nerve endings which were previously sending pain signals to the brain as a result of hibernating tissue. In one embodiment in accordance with the present invention, a fluid under pressure is forced into the wound formed by PMR. This fluid may include saline, contrast media, a therapeutic agent, a caustic agent, or any combination of these. Means for detecting contact 706 may be used to verify that

electrode 30 is in contact with myocardial tissue when the fluid is delivered. Injecting a fluid including a radiopaque contrast media creates a radiopaque marker of the treatment site. Injecting a fluid including a therapeutic agent into the wound may enhance the angiogenic response of the body. Forcing fluid under
5 pressure into the wound may also create collateral damage within an area proximate the wound. This collateral damage may include the rupturing of blood vessels, capillaries, and sinuses within the myocardium. This collateral damage will increase the healing response by angiogenesis.

A number of methods have been used to create channels in the
10 myocardium during percutaneous myocardial revascularization. Methods of cutting include the use of knife-like cutting tools and cutting with light from a LASER. Radio frequency energy may also be used to burn or ablate channels or craters into myocardial tissue.

15 Summary of the Invention

The present invention relates to methods and devices for performing percutaneous myocardial revascularization without interfering with the blood pumping activity of the heart. A desirable feature of the present invention is that the delivery of radio frequency energy to an area proximate the heart is
20 discontinued when the heart is in a vulnerable period of the cardiac rhythm. A second desirable feature of the present invention is that the discharge of electrical energy stored in the heart is disallowed during vulnerable periods of each heart beat.

A system for performing percutaneous myocardial revascularization in accordance with the present invention typically includes an active electrode disposed at the end of a catheter, and a radio frequency generator coupled to the active electrode. The PMR system further includes a means for patient
5 monitoring capable of detecting electrical activity in the heart of a patient. Radio frequency energy is selectively applied to the active electrode only when the heart is not in a vulnerable stage of the cardiac rhythm.

Embodiments of a percutaneous myocardial revascularization system in accordance with the present invention may also include provisions to assure that
10 the active electrode is properly positioned. In one embodiment of the present invention an impedance means is coupled between the active electrode and the radio frequency generator. The impedance value of the impedance means is selected so that maximum power transfer will occur when the active electrode is in contact with the myocardial tissue of the patient's heart. To accomplish this,
15 the impedance value of the impedance means is selected so that the impedance of the PMR system is substantially equal to the load impedance which will be encountered by the system when the active electrode contacts the myocardial tissue of the patient's heart.

An additional embodiment of the present invention includes a means for
20 detecting contact between the active electrode and the myocardial tissue of a patient's heart. This embodiment is for use with a method of PMR during which a high level of radio frequency energy is not applied to the active electrode until contact between the active electrode and myocardial tissue has been detected. A

relatively low level of radio frequency energy is utilized to detect contact between the active electrode and myocardial tissue. A high level of radio frequency energy is selectively applied to the active electrode only after contact has been verified.

- 5 A method in accordance with the present invention avoids discharging high levels of radio frequency energy into the blood. The discharge of high levels of radio frequency energy into the blood may cause complications such as platelet damage, gas bubbles, and blood clots.

10 Brief Description of the Drawings

Figure 1 is a schematic diagram of a circuit modeling the human heart muscle;

Figure 2 is an electrocardiograph wave form representing a single heart beat;

- 15 Figure 3 is a block diagram of a PMR system in accordance with the present invention;

Figure 4 is a block diagram of an alternate embodiment of a PMR system in accordance with the present invention;

- Figure 5 is a block diagram of an additional embodiment of a PMR system
20 in accordance with the present invention;

Figure 6 is a block diagram of an additional embodiment of a PMR system in accordance with the present invention;

Figure 7 is a block diagram of an additional embodiment of a PMR system in accordance with the present invention; and

Figure 8 is a block diagram illustrating one embodiment of a contact detecting means in accordance with the present invention.

5

Detailed Description of the Invention

The following detailed description should be read with reference to the drawings, in which like elements in different drawings are numbered identically. The drawings which are not necessarily to scale, depict selected embodiments and
10 are not intended to limit the scope of the invention.

Examples of constructions, materials, dimensions, and manufacturing processes are provided for selected elements. All other elements employ that which is known to those of skill in the field of the invention. Those skilled in the art will recognize that many of the examples provided have suitable alternatives
15 which may be utilized.

Figure 1 is a schematic diagram of a circuit 10 modeling the human heart muscle. As shown in the circuit of Figure 1, the endocardium and the myocardium of the heart exhibit a combination of capacitance, resistance and rectifying elements. Applicant has found that the capacitor is a dominant
20 component in this model. The capacitive element in this model represents the ability of the heart to store an electrical charge. It is a desirable feature of the present invention that the discharge of this electrical energy is disallowed during vulnerable periods in each heartbeat.

Figure 2 is an electrocardiograph waveform 50 representing a single heartbeat. As shown in Figure 2, each heartbeat may be represented as a complex wave comprised of five component waves designated "P", "Q", "R", "S" and "T" waves. The first component wave is the P-wave which electronically represents
5 an atrial beat associated with atrial depolarization which commands heart rate as a function of signals from the rest of the body depicting the required cardiac output.

The main feature of the electrocardiogram signal is the R-wave which is a generally triangular pulse representing the electrical actuation of the ventricles. The R-wave is the electrical activity in the heart which stimulates a ventricular
10 contraction. The T-wave portion of each heartbeat follows the R wave by about 0.3 seconds. The T-wave indicates the repolarization of the ventricles. During the repolarization of the ventricles the heart rhythm is vulnerable to disruption by electrical current passing through the heart or proximate the heart. More particularly, ventricular fibrillation may be induced by an electric current passing
15 through the heart during ventricular depolarization. Ventricular fibrillation is a rapid, and disorganized firing of muscle fibers within the ventricular myocardium. During ventricular fibrillation, the ventricles do not contract in an organized manner, no blood is pumped, and blood pressure falls to zero. Patient death may occur within 4 minutes from the onset of ventricular fibrillation. Other cardiac
20 arrhythmias may occur as a result of electric current traveling through or proximate the heart during a vulnerable period. Examples of other arrhythmia's which may occur include tachycardia.

As shown in the heart equivalent circuit of Figure 1, the heart muscle is capable of storing an electrical charge. As described previously, it is a desirable feature of the present invention that the discharge of this electrical energy is disallowed during the vulnerable periods of each heartbeat. In particular, the
5 discharge of electrical energy stored in the heart is disallowed in order to reduce the likelihood of unintentionally triggering ventricular fibrillation or other arrhythmia's.

Figure 3 is a block diagram of a PMR system 100 in accordance with the present invention. PMR system 100 includes a catheter 102 adapted to be
10 received in the vasculature of a patient. An active electrode 104 is disposed on the distal end of catheter 102. Electrode 104 is coupled to a radio frequency generator 106. Generator 106 is capable of acting as a source of radio frequency energy for ablating tissue during a PMR procedure.

PMR system 100 includes a return electrode 108 which is adapted for
15 connection to the body of a patient. Return electrode 108 in the embodiment of Figure 3 is pictured as a flat pad. A return electrode of this type typically includes a flexible conductive pad which conforms to the contours of a patients body. Materials suitable for this conductive pad include metal foil and conductive ink disposed on a polymer substrate. Return electrodes of this type are typically
20 adhered to the outside of a patients body with an interface material which is both conductive and sticky, such as a hydrogel adhesive. This configuration of an active electrode disposed on a cutting tool, and passive electrode pad is sometimes referred to as a monopolar configuration.

Bipolar embodiments of the present invention have also been envisioned. In a bi-polar configuration, a return, or neutral electrode is disposed in close proximity to the active electrode. For example, in the embodiment of Figure 3 a return electrode could be disposed on the outer surface of catheter 102 proximate active electrode 104. Those with skill in the art will recognize that methods and devices in accordance with the present invention may be used with bipolar or monopolar PMR techniques.

As shown in Figure 3, a switching means 110 is coupled to both return electrode 108 and generator 106. Switching means 110 is capable of alternating between a closed circuit state and an open circuit state. When switching means 110 is in a closed circuit state it completes an electrical connection between return electrode 108 and RF generator 106. Although in the embodiment of Figure 3, switching means 110 is coupled between generator 106 and return electrode 108, other locations for switching means 110 are possible without deviating from the spirit and scope of the present invention. For example, switching means 110 may be coupled between active electrode 104 and generator 106.

A controller 112 is coupled to switching means 110. Controller 112 is capable of changing the state of switching means 110 from an open circuit condition to a closed circuit condition or from a closed circuit condition to an open circuit condition. An electrocardiogram (ECG) signal sensing means 114 is coupled to controller 112. A plurality of ECG electrodes 116 are coupled to ECG sensing means 114. ECG electrodes 116 are adapted to make electrical contact with the body of a patient. ECG electrodes 116 may be placed on the skin, or

disposed inside the body of a patient. Although three ECG electrodes 116 are illustrated in the embodiment of Figure 3, those with skill in the art will understand that more or fewer ECG electrodes 116 may be utilized without deviating from the spirit or scope of the present invention. ECG electrodes 116
5 and ECG sensing means 114 are capable of collecting an ECG signal representative of a patient's cardiac rhythm.

As described above, switching means 110 is capable of creating an open circuit condition between return electrode 108 and generator 106. During a PMR procedure, switching means 110 may be utilized to reduce the likelihood of
10 unintentionally inducing cardiac fibrillation. Switching means 110 is capable of interrupting the conduction of radio frequency energy to the patient by creating an open circuit. Switch means 110 is also capable of preventing the stored electrical charge within the patient's body from dissipating through the PMR system.

As shown in the heart equivalent circuit of Figure 1, the heart muscle is
15 capable of storing an electrical charge. As described previously, it is a desirable feature of the present invention that the discharge of this electrical energy is disallowed during the vulnerable periods of each heartbeat. In particular, the discharge of electrical energy stored in the heart is disallowed in order to reduce the likelihood of unintentionally inducing ventricular fibrillation or other
20 arrhythmia's. Creating an open circuit between the patient and the PMR system prevents electrical charge stored in the patient's body from dissipating through the PMR system.

It is an additional desirable feature of the present invention that the delivery of radio frequency to the myocardium is interrupted during vulnerable periods of the cardiac rhythm. In the embodiment of Figure 3, switching means 110 is utilized to create an open circuit between return electrode 108 and
5 generator 106 halting the delivery of radio frequency energy to the patient. Halting the delivery of radio frequency energy during vulnerable periods of the cardiac rhythm reduces the likelihood that ventricular fibrillation or other arrhythmia's will be induced by the PMR procedure.

As described above, ECG sensing means 114 and ECG electrodes 116 are
10 capable of collecting an ECG signal from the patient. Controller 112 processes the ECG signal to identify vulnerable periods during which it is likely that the cardiac rhythm will be disrupted by electrical current passing through the heart or proximate the heart. In a presently preferred embodiment, controller 112 identifies the T-wave portion of the ECG signal. When controller 112 determines
15 that the heart is in a vulnerable period, it actuates switching means 110 to an open circuit state. When the vulnerable period is over, switching means 110 may be returned to a closed state by controller 112.

A method of percutaneous myocardial revascularization in accordance with the present invention typically includes the step of introducing catheter 100
20 into the vasculature of the patient. Catheter 100 is preferably advanced through the vasculature of a patient until active electrode 104 is proximate the endocardium of the patient's heart. The route taken by catheter 100 will normally be by way of the femoral artery and the aorta to the left ventricle. Additional

routes that may be taken include the carotid, radial and septal approach. To facilitate the advancement of catheter 100 through the vasculature of the patient, catheter 100 may include a slippery material, such as a hydrogel, disposed on its outer surfaces. Once inside the heart, active electrode 104 of catheter 100 is
5 positioned proximate the endocardium, preferably, such that active electrode 104 is in direct contact with the endocardium. Active electrode 104 may then be energized to form a wound.

Typically, an additional step in a method in accordance with the present invention is to identify areas of tissue within the patient's heart which are
10 candidates for PMR. To facilitate ease of discussion, areas of tissue in the heart muscle may be generally classified healthy or hibernating. Healthy tissues is tissue which is well perfused with blood, and subsequently well supplied with oxygen. Hibernating tissue is tissue which is not currently contracting to assist in the pumping of blood. However, if hibernating tissue is adequately supplied with
15 blood, it will once again begin contracting and contributing to the pumping of blood.

A number of methods may be used to identify hibernating tissue. For example, contrast media may be injected into the coronary vessels to identify regions of the heart into which the contrast medium does not flow due to
20 obstruction of the vessels into which the media was injected. In this case, the hibernating region will be identified by the lack of flow or abnormally low flow distally of the obstruction in the coronary vessel or vessels.

A second method which may be used to identify hibernating regions of the heart involves injecting contrast media directly into the heart chambers. Hibernating tissue may then be identified by locating areas of generally poor wall motion of the heart chambers. When this method is selected, the contrast media
5 may be delivered to the heart chambers via catheter 100. One or more lumens may be disposed in catheter 100 to provide a suitable channel for delivering contrast media from a location outside the patient's body to the distal end of catheter 100 disposed inside the patient's body.

During a PMR procedure, active electrode 104 is disposed proximate the
10 heart tissue targeted for PMR treatment. Active electrode 104 is then energized with radio frequency energy from generator 106 and active electrode 104 proceeds to burn or ablate heart tissue. Throughout the PMR procedure, the patient's ECG signal is collected by ECG sensing means 114 and monitored by controller 112. When controller 112 detects a vulnerable period of the heart's
15 activity it sends a signal to switching means 110 causing switching means 110 to create an open circuit condition between return electrode 108 and generator 106. This open circuit condition interrupts the delivery of RF energy from active electrode 104. This open circuit condition also prevents charge stored in the heart from dissipating. Preventing electrical activity proximate the heart during
20 vulnerable periods reduces the likelihood of unintentionally inducing ventricular fibrillation or other arrhythmias.

Figure 4 is a block diagram of an additional embodiment of a PMR system 100. PMR system 100 includes a catheter 102 adapted to be received in the

vasculature of a patient. An active electrode 104 is disposed on the distal end of catheter 102. Electrode 104 is coupled to an impedance means 120. Impedance means 120 is coupled to a radio frequency generator 106. As in the previous embodiment, generator 106 is capable of energizing active electrode 104 with
5 radio frequency energy to ablate tissue during a PMR procedure.

Impedance means 120 may include active or passive components such as capacitors, inductors, resistors, transistors or the like or any combination thereof. In a presently preferred embodiment, impedance means 120 is a capacitor.

PMR system 100 includes a return electrode 108 which is adapted for
10 connection to the body of a patient. Return electrode 108 in the embodiment of Figure 4 is pictured as a flat pad. A return electrode of this type typically includes a flexible conductive pad which conforms to the contours of a patients body. Materials suitable for this conductive pad include metal foil and conductive ink disposed on a polymer substrate. Return electrodes of this type typically are
15 adhered to the outside of a patients body with an interface material which is both conductive and sticky, such as a hydrogel adhesive. This configuration of active and passive electrodes is sometimes referred to as a monopolar configuration.

Bipolar embodiments of the present invention have also been envisioned. In a bi-polar configuration, a return, or neutral electrode is disposed in close
20 proximity to the active electrode. For example, in the embodiment of Figure 4 a return electrode could be disposed on the outer surface of catheter 102 proximate active electrode 104. Those with skill in the art will recognize that methods and

devices in accordance with the present invention may be used with bipolar or monopolar PMR techniques.

As shown in Figure 4, a switching means 110 is coupled to both return electrode 108 and generator 106. Switching means 110 is capable of alternating
5 between closed circuit and open circuit states. When switching means 110 is in a closed circuit state it completes an electrical connection between return electrode 108 and RF generator 106. Although in the embodiment of Figure 4, switching means 110 is coupled between generator 106 and return electrode 108, other locations for switching means 110 are possible without deviating from the spirit
10 and scope of the present invention. For example, switching means 110 may be coupled between active electrode 104 and generator 106.

A controller 112 is coupled to switching means 110. Controller 112 is capable of change the state of switching means 110 from an open circuit condition to a closed circuit condition or from a closed circuit condition to a closed circuit
15 condition. An ECG sensing means 114 is coupled to controller 112. A plurality of ECG electrodes 116 are coupled to ECG sensing means 114. ECG electrodes 116 are adapted to make electrical contact with the body of a patient. ECG electrodes may be placed on the skin, or disposed inside the body. Although three ECG electrodes 116 are illustrated in the embodiment of Figure 4, those with skill
20 in the art will understand that more or fewer ECG electrodes 116 may be utilized without deviating from the spirit or scope of the present invention.

As described above, switching means 110 is capable of creating an open circuit condition between return electrode 108 and generator 106. During a PMR

procedure, switching means 110 may be utilized to reduce the likelihood of unintentionally inducing cardiac fibrillation. Switching means 110 is capable of interrupting the conduction of radio frequency energy to the patient by creating an open circuit. Switch means 110 is also capable of preventing the stored electrical
 5 charge within the patient's body from dissipating through the PMR system.

The impedance value of impedance means 120 is selected so that maximum power transfer will occur when active electrode 104 is in contact with the myocardial or endocardial tissue of the patient's heart. To accomplish this, the impedance value of impedance means 104 is selected so that impedance of the
 10 PMR system is substantially equal to the load impedance which will be encountered when the active electrode contacts the myocardial or endocardial tissue of the patient's heart.

As described above, maximum power transfer occurs when the impedance of the PMR system is equal to the load impedance. This relationship may be
 15 demonstrated mathematically beginning with an equation describing the average power delivered to the load (i.e. the patient).

$$P = |I|^2 R_L$$

Equation 1

20 Where I is the load current and R_L is the resistance of the load. Load current may be calculated as follows:

$$I = \frac{V_{Th}}{(R_{Th} + R_L) + j(X_{Th} + X_L)}$$

Equation 2

Where R_{Th} is the Thevenin equivalent impedance of the PMR system and V_{Th} is the Thevenin equivalent voltage delivered by the PMR system.

5 Substituting equation 2 into equation 1 yields:

$$P = \frac{|V_{Th}|^2 R_L}{(R_{Th} + R_L)^2 + (X_{Th} + X_L)^2}$$

Equation 3

P will be maximized when dP/dR_L and dP/dX_L are both zero.

$$\frac{\partial P}{\partial X_L} = \frac{-|V_{Th}|^2 2R_L (X_L + X_{Th})}{[(R_L + R_{Th})^2 + (X_L + X_{Th})^2]^2}$$

Equation 4

10

$$\frac{\partial P}{\partial R_L} = \frac{|V_{Th}|^2 [(R_L + R_{Th})^2 + (X_L + X_{Th})^2 - 2R_L (R_L + R_{Th})]}{[(R_L + R_{Th})^2 + (X_L + X_{Th})^2]^2}$$

Equation 5

An evaluation equation 5 reveals that dP/dX_L will be zero when:

$$X_L = X_{Th}$$

15

Equation 6

An evaluation of equation 6 reveals that dP/dR_L will be zero when:

$$R_L = \sqrt{R_{Th}^2 + (X_L + X_{Th})^2}$$

5 Equation 7

An examination of equations 7 and 8 reveals that both derivatives will be zero when:

$$Z_L = Z_{Th}^*$$

Equation 8

10

The maximum average power is delivered to the load when Z_L is equal to the conjugate of Z_{Th} . In one embodiment of the present invention, the load impedance when the active electrode contacts myocardial tissue is equal to the conjugate of the impedance of the PMR system. It should be understood that
15 other embodiments of the present invention are possible. For example the impedance of the PMR system may be a value which is not an exact conjugate match to the impedance of the patient without deviating from the spirit and scope of the present invention. For example, in some applications it may be adequate for the impedance of the PMR system to be substantially equal to the load
20 impedance when the active electrode contacts the myocardial tissue.

If active electrode 104 loses contact with the myocardial tissue of the patient's heart during a PMR procedure, the load impedance value will change to a

value which is not equal to the impedance of the PMR system. When the load impedance is no longer matched to the impedance of the PMR system, the level of power transfer will be reduced. As described previously it is a desirable feature of the present invention to reduce the power level used during a PMR procedure

5 when the active electrode is not properly positioned.

The resulting impedance mismatch causes a reduction in the power transferred by the PMR system. It is a desirable feature of this embodiment of a PMR system that the power transferred to the patient is reduced at times when the active electrode is not in contact with myocardial tissue. In clinical use, this

10 situation may occur when the motion of the heart walls due to the blood pumping action of the heart causes the active electrode to lose contact with the myocardial tissue for a period of time during a PMR procedure. Contact between the active electrode and the myocardial tissue may also be lost due to the difficulties inherent in the use of minimally invasive surgical techniques.

15 A method of percutaneous myocardial revascularization in accordance with the embodiment of Figure 4 typically includes the step of introducing catheter 100 into the vasculature of the patient. Catheter 100 is preferably advanced through the vasculature of a patient until active electrode 104 is proximate the endocardium of a patient's heart. The route taken by catheter 100

20 will normally be by way of the femoral artery and the aorta to the left ventricle. Additional routes which may be taken include carotid, radial and septal approaches. To facilitate the advancement of catheter 100 through the vasculature

of the patient, catheter 100 may include a slippery material, such as a hydrogel disposed on its outer surfaces.

Once inside the heart, active electrode 104 of catheter 100 is positioned proximate the heart tissue targeted for PMR therapy. It is preferred that active
5 electrode 104 be in direct contact with the myocardium or the endocardium. Active electrode 104 is then energized with radio frequency energy from generator 106. If active electrode 104 is in contact with the myocardium/endocardium when active electrode 104 is energized, the transfer of energy from the PMR system to the patient will be maximized from the outset. If
10 active electrode 104 is not in contact with the myocardium/endocardium when active electrode 104 is energized, energy will be transferred to the patient at a lower level.

If active electrode 104 loses contact with the myocardial tissue of the patient's heart, the load impedance value will change to a value which is not equal
15 to the impedance of the PMR system. When the load impedance is no longer matched to the impedance of the PMR system, the level of power transfer will be reduced. As described previously it is a desirable feature of the present invention that the power is reduced when the active electrode is not properly positioned.

In a clinical environment, active electrode 104 may lose contact with the
20 heart tissue due to the blood pumping action of the heart. Contact between the active electrode and the myocardial tissue may also be lost due to the difficulties inherent in the use of minimally invasive surgical techniques. When these events occur, the resulting impedance mismatch causes a reduction in the power

transferred by the PMR system. It is a desirable feature of this embodiment of a PMR system that the power transferred to the patient is reduced at times when the active electrode is not in contact with myocardial tissue.

Figure 5 is a block diagram of an additional embodiment of a PMR system

5 100. PMR system 100 includes a catheter 102 adapted to be received in the vasculature of a patient. An active electrode 104 is disposed on the distal end of catheter 102. Electrode 104 is coupled to an variable impedance means 122. Variable impedance means 122 is coupled to a radio frequency generator 106. As in the previous embodiments, generator 106 is capable of energizing active
10 electrode 104 with radio frequency energy to ablate tissue during a PMR procedure.

As described above, the embodiment of PMR system 100 illustrated in Figure 5 includes a variable impedance means 220. Variable impedance means 220 is coupled to an impedance selection means 222. Impedance selection means
15 222 is coupled to an input means 224. Input means 224 provides a physician or other user of PMR system 100 to enter information pertaining to the PMR procedure presently being performed. This information may include the model number of catheter 102, the surface area of active electrode 104, the weight of the patient, the desired voltage, etc.

20 Variable impedance means 220 may include active or passive components such as capacitors, inductors, resistors, transistors or the like, or any combination thereof. In a presently preferred embodiment, variable impedance means 220 is a network of capacitors and solid state switching devices. In this presently

preferred embodiment, the impedance of variable impedance means may be varied by switching capacitors in or out of the network. The impedance value of variable impedance means 220 is selected by impedance selection means 222. In the preferred embodiment described above, impedance selection means 222
5 controls the state of the solid state switches in variable impedance means 220.

Information entered into PMR system 100 via input means 224 is utilized to select an appropriate value for variable impedance means 220. In a presently preferred embodiment, the impedance value selected by impedance selection means 222 is based on the geometry of active electrode 104 included in a
10 particular catheter 100. Also in a presently preferred embodiment, impedance selection means 222 includes stored information useful for selecting an appropriate impedance value. This information may include impedance values appropriate for each model of catheter and each voltage level. Other factors may be used in determining appropriate impedance values without deviating from the
15 spirit or scope of the present invention. In any case, the impedance value of variable impedance means 220 is selected so that maximum power transfer occurs when active electrode 104 is in contact with myocardial/endocardial tissue.

A method of percutaneous myocardial revascularization in accordance with the embodiment of Figure 5 typically begins with the step of entering
20 information pertaining to the PMR procedure presently being performed. A physician or other user of PMR system 100 may enter this information via input means 224. Impedance selection means 222 uses the information entered via

input means 224 along with information stored in memory to select an appropriate impedance value for the present PMR procedure.

A method of percutaneous myocardial revascularization in accordance with the embodiment of Figure 5 also typically includes the step of introducing
5 catheter 100 into the vasculature of the patient. Catheter 100 is preferably advanced through the vasculature of a patient until active electrode 104 is proximate the endocardium of a patient's heart. The route taken by catheter 100 will normally be by way of the femoral artery and the aorta to the left ventricle. Additional routes which may be taken include carotid, radial and septal
10 approaches. To facilitate the advancement of catheter 100 through the vasculature of the patient, catheter 100 may include a slippery material, such as a hydrogel disposed on its outer surfaces.

Once inside the heart, active electrode 104 of catheter 100 is positioned proximate the heart tissue targeted for PMR therapy. It is preferred that active
15 electrode 104 be in direct contact with the myocardium or the endocardium. Active electrode 104 is then energized with radio frequency energy from generator 106. If active electrode 104 is in contact with the myocardium/endocardium when active electrode 104 is energized, the transfer of energy from the PMR system to the patient will be maximized from the outset. If
20 active electrode 104 is not in contact with the myocardium/endocardium when active electrode 104 is energized, energy will be transferred to the patient at a lower level.

If active electrode 104 loses contact with the myocardial tissue of the patient's heart, the load impedance value will change to a value which is not equal to the impedance of the PMR system. When the load impedance is no longer matched to the impedance of the PMR system, the level of power transfer will be reduced. As described previously it is a desirable feature of the present invention that the power is reduced when the active electrode is not properly positioned.

In a clinical environment, active electrode 104 may lose contact with the heart tissue due to the blood pumping action of the heart. Contact between the active electrode and the myocardial tissue may also be lost due to the difficulties inherent in the use of minimally invasive surgical techniques. When these events occur, the resulting impedance mismatch causes a reduction in the power transferred by the PMR system. It is a desirable feature of this embodiment of a PMR system that the power transferred to the patient is reduced at times when the active electrode is not in contact with myocardial tissue.

Figure 6 is a block diagram of an additional embodiment of a PMR system 100. PMR system 100 includes a tuned catheter 602 adapted to be received in the vasculature of a patient. Tuned catheter 602 includes a lead wire 604. Lead wire 604 is adapted to make a connection to a radio frequency generator 106 via a connection means 606. Tuned catheter 602 may be comprised of an elongate shaft having a distal end and a proximal end. Tuned catheter may also include a lumen extending from the distal end to the proximal end.

An impedance means 620 and a conductor 622 are disposed within tuned catheter 602. An active electrode 104 is disposed on the distal end of catheter

602. Active electrode 104 is electrically connected to generator 106 via conductor 622, impedance means 620 and lead wire 604. Generator 106 is capable of energizing active electrode 104 with radio frequency energy to ablate tissue during a PMR procedure. PMR system 100 includes a return electrode 108
5 which is adapted for connection to the body of a patient. Return electrode 108 is coupled to generator 106 via a return lead wire 608 and a switching means 110.

Impedance means 620 may include active or passive components such as capacitors, inductors, resistors, and transistors, or the like or any combination thereof. In a presently preferred embodiment, impedance means 620 is a
10 capacitor. The impedance value of impedance means 620 is selected so that maximum power transfer will occur when active electrode 104 is in contact with the myocardial tissue of the patient's heart. To accomplish this, the impedance value of impedance means 620 is selected so that impedance of the PMR system is substantially equal to the load impedance which will be encountered when the
15 active electrode contacts the myocardial tissue of the patients heart during a PMR procedure.

If active electrode 104 loses contact with the myocardial tissue of the patient's heart, the load impedance value will change to a value which is not equal to the impedance of the PMR system. When the load impedance is no longer
20 matched to the impedance of the PMR system, the level of power transfer will be reduced. As described previously it is a desirable feature of the present invention to reduce the power level used during a PMR procedure when the active electrode is not properly positioned.

The resulting impedance mismatch causes a reduction in the power transferred by the PMR system. It is a desirable feature of this embodiment of a PMR system that the power transferred to the patient is reduced at times when the active electrode is not in contact with myocardial tissue. In clinical use, the
5 situation may occur when the motion of the heart walls due to the blood pumping action of the heart cause the active electrode to lose contact with the myocardial tissue for a period of time during a PMR procedure. Contact between the active electrode and the myocardial tissue may also be lost due to the difficulties inherent in the use of minimally invasive surgical techniques.

10 A method of percutaneous myocardial revascularization in accordance with the embodiment of Figure 6 typically begins with the step of selecting a catheter for the present procedure. A physician may select a catheter based on personal preference, patient dependent parameters, or other factors. A catheter in accordance with the embodiment of Figure 6 is tuned so that maximum power
15 transfer will occur when active electrode 104 is in contact with myocardial/endocardial tissue.

A method of percutaneous myocardial revascularization in accordance with the embodiment of Figure 6 also typically includes the step of introducing the selected catheter into the vasculature of the patient. Catheter 100 is preferably
20 advanced through the vasculature of a patient until active electrode 104 is proximate the endocardium of a patient's heart. The route taken by catheter 100 will normally be by way of the femoral artery and the aorta to the left ventricle. Additional routes which may be taken include carotid, radial and septal

approaches. To facilitate the advancement of catheter 100 through the vasculature of the patient, catheter 100 may include a slippery material, such as a hydrogel disposed on its outer surfaces.

Once inside the heart, active electrode 104 of catheter 100 is positioned
5 proximate the heart tissue targeted for PMR therapy. It is preferred that active electrode 104 be in direct contact with the myocardium or the endocardium. Active electrode 104 is then energized with radio frequency energy from generator 106. If active electrode 104 is in contact with the myocardium/endocardium when active electrode 104 is energized, the transfer of
10 energy from the PMR system to the patient will be maximized from the outset. If active electrode 104 is not in contact with the myocardium/endocardium when active electrode 104 is energized, energy will be transferred to the patient at a lower level.

If active electrode 104 loses contact with the myocardial tissue of the
15 patient's heart, the load impedance value will change to a value which is not equal to the impedance of the PMR system. When the load impedance is no longer matched to the impedance of the PMR system, the level of power transfer will be reduced. As described previously it is a desirable feature of the present invention that the power is reduced when the active electrode is not properly positioned.

20 In a clinical environment, active electrode 104 may lose contact with the heart tissue due to the blood pumping action of the heart. Contact between the active electrode and the myocardial tissue may also be lost due to the difficulties inherent in the use of minimally invasive surgical techniques. When these events

occur, the resulting impedance mismatch causes a reduction in the power transferred by the PMR system. It is a desirable feature of this embodiment of a PMR system that the power transferred to the patient is reduced at times when the active electrode is not in contact with myocardial tissue.

5 Figure 7 is a block diagram of an additional embodiment of a PMR system 100 in accordance with the present invention. The embodiment illustrated in Figure 7, is a PMR system 100 for use with a method of PMR which detects contact between active electrode 104 and myocardial tissue. Detection of myocardial tissue occurs with a relatively low level of power being delivered to
10 active electrode 104. PMR system 100 of Figure 7 is capable of selectively applying a higher level of radio frequency energy when contact between active electrode 104 and the myocardial tissue has been detected.

PMR system 100 includes a catheter 102 adapted to be received in the vasculature of a patient. An active electrode 104 is disposed on the distal end of
15 catheter 102. A level selection means 700 is coupled to active electrode 104 and a radio frequency generator. As in the previous embodiments, generator 106 is capable of energizing active electrode 104 with radio frequency energy. Level selector 700 and generator 106 are adapted to selectively apply two levels of power to active electrode 104. A relatively low level of power is used to detect
20 contact between active electrode 104 and myocardial tissue. Once contact between active electrode 104 and myocardial tissue has been detected, a higher level of radio frequency energy may be applied to active electrode 104 to ablate or burn tissue.

PMR system 100 of Figure 7 also includes a current sensing means 702 which is capable of measuring the level of current delivered to active electrode 104 by generator 106 and level selector 700. Current transducers suitable for use in current sensing means 702 are commercially available. For example, a current
5 sensor suitable for some applications is commercially available from LEM USA, Inc. of Milwaukee Wisconsin.

Additionally, PMR system 100 of Figure 7 includes a voltage sensing means 704 which is capable of measuring the level of voltage delivered to active electrode 104 by generator 106 and level selector 700. Voltage transducers
10 suitable for use in voltage sensing means 704 are commercially available. For example, a voltage sensor suitable for some applications is commercially available from LEM USA, Inc. of Milwaukee Wisconsin.

A means of detecting contact 706 is coupled to current sensing means 702 and voltage sensing means 706. Contact detecting means 706 is capable of
15 detecting contact between active electrode 104 and myocardial tissue. Contact detecting means 706 is capable of monitoring, storing, and processing voltage and current waveforms from voltage sensing means 704 and current sensing means 702. Contact detecting means 706 is also coupled to level selector 700. In a presently preferred embodiment, contact detecting means 706 creates a signal
20 which enables level selector 700 to selectively apply a higher level of radio frequency energy to active electrode 104.

Figure 8 is a block diagram illustrating one embodiment of contact detecting means 706. In the embodiment of Figure 8, contact detecting means 706

includes a phase detecting means 802 which is coupled to voltage sensing means 704, current sensing means 702 and a logic operator 806. Phase detect means 802 is capable of measuring the phase angle between the current waveform and the voltage waveform. In a presently preferred embodiment, phase detect means 802
5 outputs a logic high signal to logic operator 806 when the phase angle between the current waveform and the voltage waveform is greater than 40 degrees.

Contact detecting means 706 of Figure 8 also includes an impedance detecting means 804 coupled to current sensing means 702, voltage sensing means 704, and logic operator 806. Impedance detecting means 804 is capable
10 calculating the impedance between active electrode 104 and return electrode 108. In a presently preferred embodiment, impedance detecting means 804 outputs a logic high signal to logic operator 806 when the measured impedance is greater than 300 ohms.

As shown in Figure 8, logic operator 806 performs an AND function on
15 the signals received from phase detecting means 802 and impedance detecting means 804. Logic operator 806 is coupled to level selector 700. In a presently preferred embodiment, a high level enable signal is sent to level selector 700 by logic operator 806 when the load impedance is greater than 300 ohms, and the phase angle between the current waveform and the voltage waveform is greater
20 than 40 degrees.

It should be understood that other embodiments of contact detecting means 706 are possible without deviating from the spirit and scope of the present invention. For example, contact may be detected based solely on the measured

impedance. Alternately, contact may be detected based solely on the measured phase angle. It should also be understood that the values given above for phase angle and impedance are examples and other values may be utilized without deviating from the spirit or scope of the invention.

5 The embodiment illustrated in Figure 7, is a PMR system 100 for use with a method of PMR during which a high level of radio frequency energy is not applied to active electrode 104 until contact between active electrode 104 and myocardial tissue has been detected. As described above, level selector 700 is capable of selectively applying two levels of radio frequency energy to active
10 electrode 104. A relatively low level of radio frequency energy is utilized to detect contact between active electrode 104 and myocardial tissue. A higher level of radio frequency energy is selectively applied to active electrode 104 after contact has been verified, to begin ablating or burning tissue.

 A method of percutaneous myocardial revascularization in accordance
15 with the embodiment of Figure 7 typically includes the step of introducing catheter 100 into the vasculature of the patient. Catheter 100 is preferably advanced through the vasculature of a patient until active electrode 104 is proximate the endocardium of a patient's heart. The route taken by catheter 100 will normally be by way of the femoral artery and the aorta to the left ventricle.
20 Additional routes which may be taken include carotid, radial and septal approaches. To facilitate the advancement of catheter 100 through the vasculature of the patient, catheter 100 may include a slippery material, such as a hydrogel disposed on its outer surfaces.

Once inside the heart, active electrode 104 of catheter 100 is positioned proximate the heart tissue targeted for PMR therapy. Active electrode 104 is then energized with a low level of radio frequency energy. Measurements are then made to determine if active electrode 104 is in contact with endocardial or myocardial tissue. In a presently preferred embodiment, the phase angle between the current waveform and the voltage wave form is measured. Also in a presently preferred embodiment, the impedance of the patient is measured. If the measured values are within an acceptable range of values, a higher level of radio frequency energy is applied to active electrode 104 to form a wound.

10 A PMR method in accordance with the present invention, may include the step of delivering a fluid to the wound site via catheter 102. Contact detecting means 706 may be used to verify that distal end 18 is proximate myocardial tissue before delivering the fluid. . This fluid may include saline, radiopaque contrast media, a therapeutic agent, a caustic agent, or any combination of these. Injecting
15 a fluid including a radiopaque contrast media into the wound serves to create a radiopaque marker of a treatment site. Injecting a fluid, including a therapeutic agent, serves to promote angiogenesis. The formation of the wound may also be enhanced by collateral damage to the myocardium induced by directing pressurized fluid into the wound site. The impact of the pressurized fluid causes
20 vessels, capillaries, and sinuses to rupture.

Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in

details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

What is claimed is:

1. A system for performing percutaneous myocardial revascularization, comprising:

an active electrode disposed at the end of a catheter;

a radio frequency generator coupled to the active electrode for delivering radio frequency energy thereto;

a return electrode adapted for connection to the body of a patient;

a means for switching coupled to the return electrode and the radio frequency generator and operable to create an open circuit between the radio frequency generator and the return electrode;

a means for patient monitoring capable of detecting electrical activity in the heart of a patient; and

a controller coupled to the means for patient monitoring and the means for switching;

the controller being capable of detecting a vulnerable period in the activity of the heart and responding by directing the means for switching to create an open circuit.

2. A system for performing percutaneous myocardial revascularization, comprising:

an active electrode disposed at the end of a catheter;

a radio frequency generator;

a return electrode coupled to the radio frequency generator; and

a means for impeding the flow of electric current coupled to the active electrode and the radio frequency generator;

wherein, the magnitude of the impedance created by the means for impeding the flow of electric current is selected prior to beginning percutaneous myocardial revascularization.

3. A catheter assembly for performing percutaneous myocardial revascularization, comprising:

an elongate shaft having a proximal end, and a distal end;

a lumen defined by the elongate shaft and extending through at least a portion thereof;

an electrode disposed on the distal end of the elongate shaft; and

a means for impeding the flow of electric current coupled to the electrode;

wherein, the magnitude of the impedance created by the means for impeding the flow of electric current is selected prior to beginning percutaneous myocardial revascularization.

4. A system for performing percutaneous myocardial revascularization, comprising:

an active electrode disposed at the end of a catheter;

a radio frequency generator coupled to the active electrode and capable of switching between a first level of radio frequency energy generation and a second level of radio frequency energy generation;

a return electrode adapted for connection to the body of a patient;

a means for monitoring impedance coupled to the active electrode and the return electrode;

a controller coupled to the means for monitoring impedance and the radio frequency generator;

the controller being capable of determining when the means for monitoring impedance has detected a desirable impedance and responding by directing the radio frequency generator to switch from the first energy level to the second energy level.

5. A system for performing percutaneous myocardial revascularization, comprising:

an active electrode disposed at the end of a catheter;

a radio frequency generator coupled to the active electrode and capable of switching between a first level of radio frequency energy generation and a second level of radio frequency energy generation;

a means for monitoring current coupled to the active electrode;

a means for monitoring voltage coupled to the active electrode;

a return electrode adapted for connection to the body of a patient;

a means for comparing which detects a phase shift between the current waveform and the voltage waveform; and

a controller coupled to the means for monitoring voltage, the means for monitoring current, and the radio frequency generator;

the controller being capable of detecting a desirable phase shift between the current wave form and the voltage wave form and responding to the phase shift by directing the radio frequency generator to switch from the first energy level to the second energy level.

6. A percutaneous myocardial revascularization method, comprising the steps of:

- providing an active electrode disposed at the end of a catheter;
- providing a radio frequency generator coupled to the active electrode for delivering radio frequency energy thereto;
- providing a return electrode adapted for connection to the body of a patient;
- providing a means for switching coupled to the return electrode and the radio frequency generator and operable to create an open circuit between the radio frequency generator and the return electrode;
- detecting a vulnerable period in a cardiac rhythm of the heart;
- delivering radio frequency energy to the active electrode; and
- creating an open circuit with the means for switching when the vulnerable period in the cardiac rhythm is detected.

7. A percutaneous myocardial revascularization method, comprising the steps of:

- providing an active electrode disposed at the end of a catheter;

providing a radio frequency generator coupled to the active electrode for delivering radio frequency energy thereto;

providing a means for impeding the flow of electric current coupled to the active electrode and the radio frequency generator; and

selecting the magnitude of the impedance created by the means for impeding the flow of electric current prior to delivering radio frequency energy to the active electrode; and

delivering radio frequency energy to the active electrode.

8. A percutaneous myocardial revascularization method, comprising the steps of:

providing a catheter having an active electrode disposed at the distal end thereof;

the catheter further including a lead wire and a means for impeding the flow of electric current coupled to the lead wire and the active electrode;

providing a radio frequency generator coupled to the lead wire; and

delivering radio frequency energy to the active electrode.

9. A percutaneous myocardial revascularization method, comprising the steps of:

providing an active electrode disposed at the end of a catheter;

providing a radio frequency generator coupled to the active electrode and capable of applying a first level of radio frequency energy and a second level of radio frequency energy thereto;

providing a return electrode adapted for connection to the body of a patient;

providing a means for monitoring impedance coupled to the active electrode and the return electrode;

providing a controller coupled to the means for monitoring impedance and the radio frequency generator;

applying the first level of radio frequency energy to the active electrode;

measuring the impedance between the active electrode and the return electrode; and

applying the second level of radio frequency energy to the active electrode when the measured impedance is within a desired range.

10. A percutaneous myocardial revascularization method, comprising the steps of:

providing an active electrode disposed at the end of a catheter;

providing a radio frequency generator coupled to the active electrode and capable of applying a first level of radio frequency energy and a second level of radio frequency energy thereto;

providing a means for monitoring current coupled to the active electrode and the radio frequency generator and capable of detecting a current waveform;

providing a return electrode adapted for connection to the body of a patient;

providing a means for monitoring voltage coupled to the active electrode and the return electrode and capable of detecting a voltage waveform;

applying the first level of radio frequency energy to the active electrode;

measuring between the current waveform and the voltage waveform; and

applying the second level of radio frequency energy to the active electrode when the measured phase shift is within a desired range.

10




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/49954 A3

(51) International Patent Classification⁷: A61B 18/12,
18/14

(74) Agents: SEAGER, Glenn, M. et al.; Crompton, Seager
& Tufte, LLC, 331 Second Avenue South, Suite 895, Min-
neapolis, MN 55401 (US).

(21) International Application Number: PCT/US00/04973

(81) Designated States (*national*): CA, JP.

(22) International Filing Date: 24 February 2000 (24.02.2000)

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(25) Filing Language: English

(26) Publication Language: English

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

(30) Priority Data:
09/256,958 24 February 1999 (24.02.1999) US


(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];
One SciMed Place, Maple Grove, MN 55311 (US).

(88) Date of publication of the international search report:
21 December 2000

(72) Inventors: WENTZEL, David, E.; 18305 Southeast
Newport Way, Issaquah, WA 98027 (US). KAVECKIS,
Ryan; 2811-84th Avenue West, #101, Seattle, WA 98115
(US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DEVICE AND METHOD FOR PERCUTANEOUS MYOCARDIAL REVASCULARIZATION



(57) Abstract: Methods and devices for performing percutaneous myocardial revascularization without disrupting the blood pump-
ing activity of the heart. A percutaneous myocardial revascularization system including an active electrode disposed at the end of
a catheter and a radio frequency generator coupled to the active electrode for delivering radio frequency energy thereto. Radio fre-
quency energy is selectively applied to the active electrode when the active electrode is properly positioned and when the heart is not
in a vulnerable stage of the cardiac rhythm.

WO 00/49954 A3

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 00/04973

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B18/12 A61B18/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 860 951 A (EGGERS PHILIP E ET AL) 19 January 1999 (1999-01-19) abstract; figure 11 ---	1
A	DE 195 37 084 A (KLOESS WOLFGANG ;SIEVERS HANS HINRICH PROF DR M (DE)) 10 April 1997 (1997-04-10) abstract ---	1
A	EP 0 553 576 A (LASER ENG INC) 4 August 1993 (1993-08-04) column 3, line 1 -column 4, line 15 ---	1
A	EP 0 858 779 A (ECLIPSE SURGICAL TECH) 19 August 1998 (1998-08-19) column 4, line 21-38 -----	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *@* document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report

24 10. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentean 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

PAPONE, F

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/US 00/04973

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 6-10
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

~~see additional sheet~~

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claim : 1

RF percutaneous myocardial revascularization device (PMR)
capable of detecting electrical activity in the heart

2. Claims: 2,3

RF percutaneous myocardial revascularization device(PMR)
with means to select output impedance

3. Claim : 4

RF percutaneous myocardial revascularization device(PMR)
having two levels of energy output one for impedance
measuring and the other for tissue destruction

4. Claim : 5

RF percutaneous myocardial revascularization (PMR) having two
levels of energy output one to measure phase shift and the
other to fire energy at desired phase shift level

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/US 00/04973

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5860951 A	19-01-1999	US 5683366 A	04-11-1997
		US 5697281 A	16-12-1997
		US 5366443 A	22-11-1994
		AU 709928 B	09-09-1999
		AU 1057197 A	11-06-1997
		CA 2237795 A	29-05-1997
		EP 1036547 A	20-09-2000
		EP 0865256 A	23-09-1998
		JP 3033848 B	17-04-2000
		JP 11502144 T	23-02-1999
		NZ 323589 A	29-07-1999
		US 6032674 A	07-03-2000
		US 6102046 A	15-08-2000
		WO 9718768 A	29-05-1997
		US 5873855 A	23-02-1999
		AU 706294 B	10-06-1999
		AU 6026696 A	30-12-1996
		CA 2221330 A	19-12-1996
		EP 0837647 A	29-04-1998
		JP 2912023 B	28-06-1999
		JP 10510745 T	20-10-1998
		US 6063079 A	16-05-2000
		US 6053172 A	25-04-2000
		WO 9639914 A	19-12-1996
		US 6086585 A	11-07-2000
		US 6066134 A	23-05-2000
		US 5697882 A	16-12-1997
		US 6024733 A	15-02-2000
		US 5810764 A	22-09-1998
		US 5843019 A	01-12-1998
		US 5902272 A	11-05-1999
		US 5697536 A	16-12-1997
		US 5871469 A	16-02-1999
		US 6105581 A	22-08-2000
		US 6113597 A	05-09-2000
		US 6109268 A	29-08-2000
		AU 711197 B	07-10-1999
		AU 2472497 A	14-08-1997
		AU 676329 B	06-03-1997
		AU 6829694 A	12-12-1994
		CA 2162395 A	24-11-1994
		EP 0697841 A	28-02-1996
		JP 2931102 B	09-08-1999
		JP 9501328 T	10-02-1997
		NZ 266678 A	19-12-1997
		WO 9426228 A	24-11-1994
		US 5681282 A	28-10-1997
		US 5888198 A	30-03-1999
		US 5891095 A	06-04-1999
		AT 173903 T	15-12-1998
DE 19537084 A	10-04-1997	NONE	
EP 0553576 A	04-08-1993	CA 2060145 A,C	29-07-1993
		US 5125926 A	30-06-1992
		DE 69210007 D	23-05-1996
		DE 69210007 T	19-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04973

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0858779 A	19-08-1998	US 6027497 A	22-02-2000
		AU 5279898 A	26-03-1998
		CA 2228935 A	03-08-1998
		JP 10229988 A	02-09-1998
